Global Vaccine Safety Project (GCoVS)

Global Vaccine Safety Project

This initiative, led by the Global Vaccine Data Network (GVDN) and supported by funding from the U.S. Centers for Disease Control and Prevention (CDC), aims to evaluate the safety of COVID-19 vaccines across diverse and extensive study populations, leveraging the participation of 26 countries within the GVDN consortium. VAC4EU serves as the coordinating center for European sites, including the Drug Safety Research Unit, Fisabio, IDIAPJGol, and the Fundació Hospital Universitari Vall d’Hebron. The project’s objective is to contribute to the investigation of the potential association between COVID-19 vaccines and adverse reactions such as myocarditis/pericarditis, vaccine-induced immune thrombotic thrombocytopenia, Guillain-Barré syndrome, and any underlying genetic predispositions to these reactions. Interim results of these studies have been presented in the GVDN Symposium and will soon be submitted for peer review publications. This study presents an exciting opportunity to implement innovative approaches to case validation and participant consent for specimen collection, paving the way for innovative in vaccine safety research.